Cadex Genomics

At Cadex Genomics, we are interrogating a late-stage cancer patient's blood to determine if a tumor is growing early in a line of therapy and identify non-effective therapy in 12-21 days after starting a cycle of therapy versus waiting 8-12 weeks. issuu.com/mdnext/docs/md…

We're excited to have a new channel with which to showcase the entrepreneurs, physicians, dentists, investors & Industry stakeholders advancing healthcare innovation day in and day out.

Please join Cadex Genomics and AngelMD Capital at a webinar on Wednesday, August 17th to learn more about real-time therapy monitoring for cancer patients. Save your seat: docs.google.com/forms/d/e/1FAI…

Bill & the Cadex Genomics team are tackling an incredibly important part of the fight against Stage IV cancers.

New Episode: @CadexGenomics is taking the fight to Stage IV #cancer apple.co/3wz9Cs8 #genomics #diagnostic

#PitchClub starts at 6PM MT. Hear from @CadexGenomics & @scriptchain1. #startups #physicians #familyoffice #venturecapital #free bit.ly/3DF8ZiK

Today's #PitchClub revolves around #innovation in #Biotech, #Lab and #Precision medicine. Join us at 6PM MT as we have a discussion with our member startups, #healthcare experts, and innovators. To sign up, click here: bit.ly/3DF8ZiK

One of our guest speakers on our next #PitchClub is Bill Haack, CEO of Cadex Genomics. Join us with him on April 12 as we discuss more on #Innovation in #Biotech, #Lab and #Precision medicine. Register via this link: bit.ly/3DF8ZiK #AngelMD

Our next #PitchClub revolves around #innovation in #Biotech, #Lab and #Precision medicine. Join us on April 12 as we have a discussion with our member startups, #healthcare experts, and innovators. To sign up, click here: bit.ly/3DF8ZiK #AngelMD

Congratulations to the team @AxoSim.

Cadex Genomics founders Bill Haack and Greg Schafer talk about real-time cancer therapy monitoring on the MedTech Trends podcast. youtube.com/watch?v=4lvStF…

C&M intellectual property lawyers wrote about the recent Illumina v. Ariosa Diagnostics case in @IAM_Magazine, unpacking the news for diagnostics innovators. Read more: CVSoci.al/oQGn9OAp

Genetic testing for cancer, therapy monitoring, and recurrence - a +$50B addressable market. investors.com/news/technolog…

Happy to have contributed data to this important whitepaper.

"...Diagnostics have been really taken for granted Its been viewed as a commodity for the industry, an afterthought. It isn’t valued properly in the whole healthcare continuum. It isn’t paid for properly. I think that’s changing now..." medcitynews.com/2020/05/sectio…

The Daily Journal Names C&M Partner Kevin Kroeker “Top Healthcare Lawyer” CVSoci.al/uPZQ315n

New blog post: Molecular Diagnostics: A Broken Business Model or Flawed Execution? link.medium.com/xuPijvAzI5 #cancer #cancertherapymonitoring #diagnostics

Flurry of Regulatory Activity Driven by COVID-19 Anxiety Impacts Health Plan Requirements and Permissible Actions - C&M #HealthLaw CVSoci.al/7m1rfOfy

@ideapharma @matthewherper @gbmdna @chris_labarthe Hospital Food-The Eels (David Gray)

Having fun working on a playlist for the downtime at Sunday’s #unherdJPM - trying to introduce pharma humour… Y’know, stuff like: - Don’t Go Back To Rockville, REM - I Want A New Drug, Huey Lewis What am I missing? (Nominating @matthewherper, @gbmdna, @chris_labarthe to start…)